Výsledky vyhledávání - "Daniel Waterkamp"

Akademický článek

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)

Abstract Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours in two open-label

Externí odkaz: https://doaj.org/article/c7ab25df143a4df7a0b711f295ef7d2c

Zobrazit plný text záznamu

Akademický článek

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Publikováno v: Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)

Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combinat

Externí odkaz: https://doaj.org/article/6805535216ff4aaca60ddedaf5252687

Zobrazit plný text záznamu

Akademický článek

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies.

Autor: Jessica Davies, Manali Patel, Cesare Gridelli, Filippo de Marinis, Daniel Waterkamp, Margaret E McCusker

Publikováno v: PLoS ONE, Vol 12, Iss 4, p e0175679 (2017)

Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for secon

Externí odkaz: https://doaj.org/article/87769d179ebe4785ad3caf762b22b082

Zobrazit plný text záznamu

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non–small-cell lung cancer

Autor: Scott N. Gettinger, Paul Foster, D. Ross Camidge, Daniel Waterkamp, F. Stephen Hodi, Stephen V. Liu, Koho Iizuka, Rebecca S. Heist, Wei Zhang, John D. Powderly, Jeffrey Wallin, Neal Ready, Roel Funke, Giuseppe Giaccone

Publikováno v: European Journal of Cancer. 101:114-122

Background Before the availability of immunotherapy, chemotherapy was standard first-line therapy for non–small-cell lung cancer (NSCLC) lacking actionable gene alterations. Preclinical evidence suggests chemotherapy is immunomodulatory, supporting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ba82ad0c8c9e1ab6f9cf1c29cc40da2
https://doi.org/10.1016/j.ejca.2018.06.033

Zobrazit plný text záznamu

Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer

Autor: Roel Funke, Bo Liu, Paula R. Pohlmann, Erika Hamilton, Daniel Waterkamp, Sara M. Tolaney, Jennifer R. Diamond, Luciana Molinero, Sylvia Adams, John D. Powderly, Wei Zou

Publikováno v: Cancer Research. 76:P2-11

Background: Metastatic triple-negative breast cancer (mTNBC) is associated with poor prognosis, and chemotherapy remains the mainstay of treatment. Cancer immunotherapy represents a promising treatment approach for mTNBC, which is characterized by a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a11870513333bf492f1f5655fd9a8593
https://doi.org/10.1158/1538-7445.sabcs15-p2-11-06

Zobrazit plný text záznamu

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial

Autor: F. Hermann, M. Rivoire, Satvinder Mudan, Daniel Waterkamp, Ian Chau, John Bridgewater, Thomas Gruenberger, René Adam, Susan F. Lasserre, P. GarcÃa Alfonso

OLIVIA, a multinational phase II study, suggests that bevacizumab plus FOLFOXIRI improves outcomes, including response rates, resection rates, and progression-free survival, compared with bevacizumab plus mFOLFOX-6 in patients with initially unresect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b077978e9655cbbcd7669f407da39f5
http://doc.rero.ch/record/291313/files/mdu580.pdf

Zobrazit plný text záznamu

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

Autor: Cesare Gridelli, Daniel Waterkamp, Filippo de Marinis, Manali I. Patel, Margaret Elizabeth McCusker, Jessica Davies

Publikováno v: PLoS ONE
PLoS ONE, Vol 12, Iss 4, p e0175679 (2017)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aef8ad65ea26943f7529571592660aea
http://europepmc.org/articles/PMC5391942

Zobrazit plný text záznamu

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

Autor: István Láng, Janja Ocvirk, Mark P Saunders, Daniel Waterkamp, David Cunningham, Niko Andre, Dong Bok Shin, Eugenio Marcuello, Vito Lorusso, S. Osborne, Derek J. Jonker

Publikováno v: The Lancet Oncology. 14:1077-1085

Elderly patients are often under-represented in clinical trials of metastatic colorectal cancer. We aimed to assess the efficacy and safety of bevacizumab plus capecitabine compared with capecitabine alone in elderly patients with metastatic colorect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e5c9f8c5fb7855b908ea6edd0fa9a6d
https://doi.org/10.1016/s1470-2045(13)70154-2

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání